Author: ELI LILLY AND COMPANY

ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

April 17, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.

April 9, 2026

1 … 5 6 7

ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health